EU sourced oral Femara® + Letrozole SIE Clinical Trials

1 actively recruiting trial across 1 location

No change since August 2026

Pipeline

Phase 1: 1

Top Sponsors

Rovi Pharmaceuticals Laboratories1

Indications

Hormone Receptor Positive Early Breast Cancer1
Breast Cancer1
Cancer1

Beverly Hills, California1 trial

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Precision NextGen Oncology and Research Center (Investigational Site number USA-001)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.